These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 19351764)

  • 1. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
    Prado CM; Baracos VE; McCargar LJ; Reiman T; Mourtzakis M; Tonkin K; Mackey JR; Koski S; Pituskin E; Sawyer MB
    Clin Cancer Res; 2009 Apr; 15(8):2920-6. PubMed ID: 19351764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
    Andreetta C; Puppin C; Minisini A; Valent F; Pegolo E; Damante G; Di Loreto C; Pizzolitto S; Pandolfi M; Fasola G; Piga A; Puglisi F
    Ann Oncol; 2009 Feb; 20(2):265-71. PubMed ID: 18765464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
    Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
    Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Geyer CE; Forster J; Lindquist D; Chan S; Romieu CG; Pienkowski T; Jagiello-Gruszfeld A; Crown J; Chan A; Kaufman B; Skarlos D; Campone M; Davidson N; Berger M; Oliva C; Rubin SD; Stein S; Cameron D
    N Engl J Med; 2006 Dec; 355(26):2733-43. PubMed ID: 17192538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer.
    Karvellas CJ; Sawyer M; Hamilton M; Mackey JR
    Am J Clin Oncol; 2004 Aug; 27(4):364-8. PubMed ID: 15289729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
    Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition measures as a determinant of Alpelisib related toxicity.
    Shachar E; Raphael A; Katz U; Kessner R; Shachar SS
    Breast Cancer Res Treat; 2024 Jul; 206(2):369-376. PubMed ID: 38584192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
    Schwartzberg LS; Cobb P; Walker MS; Stepanski EJ; Houts AC
    Support Care Cancer; 2009 Aug; 17(8):1081-8. PubMed ID: 19148686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
    Kaufmann M; Maass N; Costa SD; Schneeweiss A; Loibl S; Sütterlin MW; Schrader I; Gerber B; Bauer W; Wiest W; Tomé O; Distelrath A; Hagen V; Kleine-Tebbe A; Ruckhaeberle E; Mehta K; von Minckwitz G;
    Eur J Cancer; 2010 Dec; 46(18):3184-91. PubMed ID: 20797843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.